Seroprevalence of Human Herpesvirus-8 in Different Patient Groups in Cambodia and Germany

Abstract

5. Hooper DC: Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clinical Infectious Diseases (1998) 27, Supplement 1 :54–63 6. Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, Kohrer K, Schmitz FJ: Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different quinolones and originating from worldwide surveillance studies during the 1997–1998 respiratory season. Antimicrobial Agents and Chemotherapy (2000) 44 :462–466 7. Gill MJ, Brenwald NP, Wise R: Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy (1999) 43 :1187–1189 8. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR: A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrobial Agents and Chemotherapy (2000) 44 :798–801 9. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. Eighth informational supplement. Approved standard M100-S8. NCCLS, Villanova, PA (1998) 10. Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC: Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrobial Agents and Chemotherapy (2000) 44 :304–310